Free Trial

Novo Nordisk A/S (NVO) Competitors

Novo Nordisk A/S logo
$56.89 +1.44 (+2.60%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$57.05 +0.16 (+0.28%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NVO vs. NVS, AZN, SNY, GSK, TAK, ARGX, ONC, BNTX, INSM, and TEVA

Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Novartis (NVS), AstraZeneca (AZN), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

Novo Nordisk A/S vs. Its Competitors

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.4%. Novartis pays out 37.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Novo Nordisk A/S has a net margin of 35.60% compared to Novartis' net margin of 25.64%. Novo Nordisk A/S's return on equity of 78.64% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis25.64% 41.08% 16.83%
Novo Nordisk A/S 35.60%78.64%24.51%

In the previous week, Novo Nordisk A/S had 95 more articles in the media than Novartis. MarketBeat recorded 119 mentions for Novo Nordisk A/S and 24 mentions for Novartis. Novartis' average media sentiment score of 1.34 beat Novo Nordisk A/S's score of 0.62 indicating that Novartis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
18 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
54 Very Positive mention(s)
9 Positive mention(s)
42 Neutral mention(s)
9 Negative mention(s)
3 Very Negative mention(s)
Positive

Novartis currently has a consensus price target of $123.50, suggesting a potential downside of 2.71%. Novo Nordisk A/S has a consensus price target of $81.00, suggesting a potential upside of 42.38%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
2 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.09
Novo Nordisk A/S
2 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.06

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$50.32B5.33$11.94B$6.8718.48
Novo Nordisk A/S$42.12B6.03$14.64B$3.6415.63

Summary

Novo Nordisk A/S beats Novartis on 11 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVO vs. The Competition

MetricNovo Nordisk A/SLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$254.42B$253.23B$5.81B$21.31B
Dividend Yield1.44%2.62%4.39%3.54%
P/E Ratio15.6330.4431.3629.10
Price / Sales6.034.71387.8754.41
Price / Cash14.6113.5938.0224.09
Price / Book9.937.529.535.47
Net Income$14.64B$8.49B$3.26B$992.74M
7 Day Performance8.51%2.66%2.14%2.67%
1 Month Performance-19.57%0.31%3.22%2.35%
1 Year Performance-58.46%-8.58%30.18%10.76%

Novo Nordisk A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVO
Novo Nordisk A/S
4.6992 of 5 stars
$56.89
+2.6%
$81.00
+42.4%
-58.5%$254.42B$42.12B15.6377,349Trending News
Analyst Forecast
Gap Up
NVS
Novartis
1.8824 of 5 stars
$123.95
-0.2%
$123.50
-0.4%
+7.1%$261.85B$50.32B18.0475,883News Coverage
Positive News
Analyst Downgrade
AZN
AstraZeneca
2.9594 of 5 stars
$79.20
+0.0%
$86.00
+8.6%
-6.6%$245.67B$54.07B29.7894,300Positive News
SNY
Sanofi
3.8103 of 5 stars
$49.94
+0.3%
$62.00
+24.1%
-8.6%$122.62B$44.46B12.0082,878Positive News
GSK
GSK
2.8604 of 5 stars
$39.09
-0.7%
$37.38
-4.4%
-5.8%$79.62B$40.10B18.0968,629Trending News
Analyst Revision
TAK
Takeda Pharmaceutical
1.2554 of 5 stars
$15.12
+0.8%
N/A+2.8%$48.09B$30.09B50.3847,455News Coverage
Analyst Downgrade
ARGX
argenex
3.9909 of 5 stars
$662.17
+1.3%
$746.81
+12.8%
+27.7%$40.52B$2.25B33.961,599News Coverage
Positive News
ONC
BeOne Medicines
0.7522 of 5 stars
$323.83
+0.8%
$330.89
+2.2%
N/A$35.49B$3.81B-187.1811,000
BNTX
BioNTech
1.7458 of 5 stars
$113.06
-0.4%
$135.80
+20.1%
+25.7%$27.16B$2.98B-70.626,772
INSM
Insmed
4.0028 of 5 stars
$128.02
+0.2%
$129.57
+1.2%
+67.3%$27.05B$363.71M-22.411,271Trending News
Analyst Forecast
Insider Trade
Analyst Revision
TEVA
Teva Pharmaceutical Industries
3.2953 of 5 stars
$18.24
+2.1%
$24.71
+35.5%
-0.5%$20.91B$16.54B-113.9736,830News Coverage
Positive News

Related Companies and Tools


This page (NYSE:NVO) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners